Get the Stockscreener App
4.18
4.57%
-0.20
After Hours:
4.30
0.12
+2.87%
Voyager Therapeutics Inc stock is traded at $4.18, with a volume of 982.12K.
It is down -4.57% in the last 24 hours and up +23.30% over the past month.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$4.38
Open:
$4.42
24h Volume:
982.12K
Relative Volume:
1.35
Market Cap:
$231.86M
Revenue:
$163.78M
Net Income/Loss:
$25.88M
P/E Ratio:
6.4308
EPS:
0.65
Net Cash Flow:
$-28.66M
1W Performance:
-1.42%
1M Performance:
+23.30%
6M Performance:
+2.96%
1Y Performance:
-32.80%
1-Day Range:
$4.15
$4.505
1-Week Range:
$3.91
$4.505
52-Week Range:
$2.645
$8.275
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
4.18 | 230.75M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Nuveen LLC Takes $368,000 Position in Voyager Therapeutics, Inc. $VYGR - MarketBeat
Voyager Therapeutics to Present at Upcoming Investor Conferences in August 2019 - GlobeNewswire
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Fly 35% But Investors Aren't Buying For Growth - 富途牛牛
Voyager Therapeutics shifts focus for ALS therapy - MSN
Published on: 2025-09-08 10:51:27 - beatles.ru
Can Voyager Therapeutics Inc. continue delivering strong returnsQuarterly Trade Report & Accurate Technical Buy Alerts - beatles.ru
Using Bollinger Bands to evaluate Voyager Therapeutics Inc.Market Performance Report & AI Powered Buy and Sell Recommendations - Newser
Is Voyager Therapeutics Inc. stock reversal real or fakePortfolio Risk Report & Weekly High Conviction Trade Ideas - Newser
What data driven models say about Voyager Therapeutics Inc.’s futureEarnings Recap Summary & High Conviction Buy Zone Alerts - Newser
Does Voyager Therapeutics Inc. stock benefit from AI growth2025 Retail Activity & Daily Market Momentum Tracking - خودرو بانک
Is Voyager Therapeutics Inc. benefiting from innovation trends2025 Technical Patterns & AI Powered Market Entry Strategies - خودرو بانک
Candlestick signals on Voyager Therapeutics Inc. stock todayPortfolio Value Report & AI Powered Market Trend Analysis - Newser
Is Voyager Therapeutics Inc.’s growth already priced inEntry Point & Fast Entry Momentum Alerts - خودرو بانک
Technical signs of recovery in Voyager Therapeutics Inc.Market Risk Report & Reliable Entry Point Trade Alerts - Newser
What is Voyager Therapeutics Inc.’s market positionLayoff News & Weekly Market Pulse Alerts - خودرو بانک
Regression analysis insights on Voyager Therapeutics Inc. performanceJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Applying Wyckoff theory to Voyager Therapeutics Inc. stockMarket Volume Summary & Expert Curated Trade Setups - Newser
Trend analysis for Voyager Therapeutics Inc. this weekJuly 2025 Gainers & Safe Capital Growth Stock Tips - Newser
Voyager Therapeutics Inc. stock daily chart insightsJuly 2025 Opening Moves & Free Weekly Watchlist of Top Performers - Newser
Can Voyager Therapeutics Inc. rally from current levelsJuly 2025 Pullbacks & AI Optimized Trading Strategy Guides - Newser
Volume spikes in Voyager Therapeutics Inc. stock – what they meanQuarterly Market Review & Step-by-Step Trade Execution Guides - Newser
What’s next for Voyager Therapeutics Inc. stock priceMarket Risk Report & AI Enhanced Execution Alerts - Newser
How to escape a deep drawdown in Voyager Therapeutics Inc.Buy Signal & Weekly Breakout Opportunity Watchlist - Newser
Reversal indicators forming on Voyager Therapeutics Inc. stockWeekly Market Outlook & Free Real-Time Volume Trigger Notifications - Newser
Detecting support and resistance levels for Voyager Therapeutics Inc.July 2025 Sector Moves & Daily Volume Surge Signals - Newser
Best data tools to analyze Voyager Therapeutics Inc. stockStock Surge & Momentum Based Trading Signals - Newser
Voyager Therapeutics Joins Citi’s Biopharma Conference 2025 - The Globe and Mail
Published on: 2025-09-03 11:38:09 - beatles.ru
Voyager Therapeutics Inc. stock trend forecastJuly 2025 Breakouts & Free Verified High Yield Trade Plans - Newser
Is Voyager Therapeutics Inc. stock influenced by commodity pricesM&A Rumor & Daily Profit Maximizing Tips - khodrobank.com
Can trapped investors hope for a rebound in Voyager Therapeutics Inc.July 2025 Levels & Verified Swing Trading Watchlist - Newser
Voyager Therapeutics: A High-Conviction Play in Neuro-Genetic Innovation - AInvest
Order Flow Trends Show Accumulation in Voyager Therapeutics Inc.Market Risk Summary & Verified Momentum Stock Ideas - beatles.ru
Voyager Therapeutics: Pioneering Non-Viral Delivery in Neurotherapeutics - AInvest
Voyager Therapeutics’ Strategic Momentum in Neurological Disease Innovation: Assessing the Investment Potential of Preclinical Pipeline and Non-Viral Delivery Platform - AInvest
Voyager Therapeutics Presents at Citi's Biopharma Back to School Conference - AInvest
Transcript : Voyager Therapeutics, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-02-2025 04 - MarketScreener
What is the dividend yield of Voyager Therapeutics Inc.Quarterly Market Summary & Verified Momentum Stock Watchlist - خودرو بانک
Relative strength of Voyager Therapeutics Inc. in sector analysis2025 Historical Comparison & Growth Focused Investment Plans - Newser
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):